Migraine and Body Composition
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01720862|
Recruitment Status : Completed
First Posted : November 2, 2012
Last Update Posted : January 28, 2016
|Condition or disease|
|Migraine With and Without Aura Chronic Migraine Healthy Controls|
|Study Type :||Observational|
|Actual Enrollment :||300 participants|
|Observational Model:||Case Control|
|Official Title:||Migraine and Body Composition|
|Study Start Date :||April 2012|
|Actual Primary Completion Date :||October 2015|
|Actual Study Completion Date :||October 2015|
Those with migraines >2 and < 12 times per month.
Those with migraines greater than 14 days per month.
Those without headaches other than occasional hangover, cold, flu headaches.
- association between migraine and obesity - evaluate serum adipokine levels [ Time Frame: 5 years ]The first aim of the proposed research is to evaluate serum adipokine levels in a clinical cohort of obese and non-obese episodic and chronic migraineurs and examine their utility as markers of the presence or absence of migraine and their relationship to headache frequency.
- association between migraine and obesity -evaluate subcutaneous adipose tissue (SAT) and its ratio to visceral adipose tissue (VAT) [ Time Frame: five years ]The second aim of the proposed research is to evaluate subcutaneous adipose tissue (SAT) and its ratio to visceral adipose tissue (VAT),in the same clinical cohort of migraineurs to determine if regional adipose tissue differences exist between: (1) episodic migraineurs, (2) chronic migraineurs and (3) controls, thus contributing to the migraine-obesity relationship.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01720862
|United States, Maryland|
|The Johns Hopkins Bayview Headache Center|
|Baltimore, Maryland, United States, 21224|
|Principal Investigator:||Barbara L Peterlin, DO||Johns Hopkins University|